Gainesville, Fla. (February 6, 2020) – Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced that it will present a corporate overview at the BIO CEO & Investor Conference, being held at the Marriott Marquis Times Square in New York City.

Presentation Details:

Date: Monday, February 10th, 2020

Time: 3:45 p.m. (ET)

Location: Wilder Room

ABOUT OXIDIEN PHARMACEUTICALS, LLC

Oxidien Pharmaceuticals is a clinical-stage biopharmaceutical company addressing a large unmet need for kidney disease. The company is focused on treating secondary hyperoxaluria using novel oral enzymatic approaches. Oxidien has a strong intellectual property position with patents pending world-wide. The leadership team has a proven track record of successful product development, regulatory approval, and operating, growing and exiting healthcare businesses. Oxidien Pharmaceuticals is located in UF Innovate the Hub – a world-recognized leader in biotechnology business incubation affiliated with one of the nation’s leading research institutions, the University of Florida. For additional information on UF Innovate the Hub please visit http://innovate.research.ufl.edu/.